Professional Documents
Culture Documents
OF
CONTENTS
Introduction ...................................................................................................................... 38
Methods for study of molecular diagnostic markets ........................................................... 38
The overall market for diagnostic technologies ................................................................. 39
Molecular diagnostic markets according to technologies ................................................... 39
Marketing strategies according to technologies .................................................................... 40
Nucleic acid isolation market ............................................................................................. 40
Market for PCR-based tests ............................................................................................... 40
Markets for PCR instrumentation ................................................................................... 40
Markets for real-time PCR and qRT-PCR ......................................................................... 41
PCR market players ..................................................................................................... 41
DNA sequencing market.................................................................................................... 42
Cytogenetic market .......................................................................................................... 42
Market for FISH technologies ........................................................................................ 42
Biochip/microarray market ................................................................................................ 43
Biosensor market ............................................................................................................. 43
Nanobiotechnology for molecular diagnostics ....................................................................... 43
Markets for gene expression technologies ........................................................................... 44
Reagents and other disposable laboratory materials ............................................................. 44
Market for immunochemistry diagnostic .............................................................................. 44
Markets for tissue diagnostics ............................................................................................ 44
Molecular diagnostic markets according to therapeutic areas ........................................... 44
Genetic disorders ............................................................................................................. 45
Prenatal testing ............................................................................................................... 46
Cancer............................................................................................................................ 46
Potential markets for cancer diagnosis according to type of cancer .................................... 47
Infectious diseases ........................................................................................................... 48
Sexually transmitted diseases....................................................................................... 50
Hospital-acquired infections.......................................................................................... 50
Testing for HIV drug resistance ..................................................................................... 51
Potential markets for avian influenza diagnostics ............................................................ 51
Cardiovascular diseases .................................................................................................... 52
Neurological disorders ...................................................................................................... 52
Food testing .................................................................................................................... 52
Screening of blood for transfusion ...................................................................................... 53
Tissue typing for transplantation ........................................................................................ 53
Molecular diagnostic markets relevant to pharmaceutical industry ................................... 53
Molecular diagnosis and personalized medicine markets........................................................ 53
Growth of markets relevant to personalized medicine ........................................................... 53
Marketing opportunities according to geographic areas .................................................... 54
Unmet needs in molecular diagnostics ............................................................................... 55
Major market trends .......................................................................................................... 55
Markets according to home-brew and FDA-approved tests .................................................... 55
Decentralization of molecular diagnostics ............................................................................ 56
Point-of-care testing......................................................................................................... 56
Development of personalized medicine ............................................................................... 57
Cost of sequencing the human genome.......................................................................... 57
Cost of genotyping ...................................................................................................... 58
Marketing companion diagnostics for personalized medicine ............................................. 58
Development of low-cost tests ........................................................................................... 59
Simplification of test procedures ........................................................................................ 59
Increasing role of proteomics in clinical diagnostics .............................................................. 59
Forensic and legal applications .......................................................................................... 60
Veterinary molecular diagnostics ........................................................................................ 60
Marketing strategies .......................................................................................................... 60
Role of alliances in commercialization of molecular diagnostics .............................................. 61
Acquisitions vs collaborations ....................................................................................... 61
Analysis of collaborations in molecular diagnostics .......................................................... 64
Licensing of the technologies ........................................................................................ 65
Strategies related to laboratory facilities and technologies .................................................... 65
Strategies relevant to the healthcare system ....................................................................... 66
Cost-Benefit studies .................................................................................................... 66
Genetic susceptibility testing ........................................................................................ 66
Preventive medicine strategies ..................................................................................... 67
Targeting treatable and common diseases...................................................................... 67
Information/education ...................................................................................................... 67
Physician education ..................................................................................................... 67
Patient education ........................................................................................................ 68
European diagnostic information platform ...................................................................... 68
Regulatory strategies ....................................................................................................... 69
Merger of in vitro and in vivo diagnostics ............................................................................ 69
Integration of diagnostics with therapeutics ........................................................................ 69
-4-
Tables
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
13-1: Share of in vitro diagnostics in the global diagnostic market 2011-2021 .......................... 39
13-2: Molecular diagnostics markets according to technologies from 2011-2021 ....................... 39
13-3: PCR market 2011-2021 ............................................................................................. 40
13-4: Molecular diagnostics markets according to applications 2011-2021................................ 45
13-5: Markets in 2011 for tests to screen healthy persons for genetic disorders ........................ 46
13-6: Markets in 2011 for molecular diagnostic screening tests for cancer ................................ 47
13-7: Molecular diagnostic markets for selected cancers 2011-2021 ........................................ 47
13-8: Markets value in 2011 for molecular diagnostic screening for infections ........................... 49
13-9: Future markets for molecular diagnosis of infections 2012-2016..................................... 49
13-10: Future markets for HAI diagnostics 2012-2016 ........................................................... 50
13-11: Growth of markets relevant to personalized medicine 2011-2021 ................................. 54
13-12: Molecular diagnostic markets according to geographical areas 2011-2021 ..................... 54
13-13: Molecular diagnostic markets according to home-brew and approved tests .................... 56
13-14: Marketing strategies for molecular diagnostics ........................................................... 60
13-15: Acquisitions of molecular diagnostic companies .......................................................... 61
13-16: Advantages of the integration of diagnostics with therapeutics ..................................... 69
14-1: Top ten players in molecular diagnostics ..................................................................... 76
14-2: Collaborations of companies in molecular diagnostics .................................................. 464
Figures
Figure 13-1: Unmet needs in applications of molecular diagnostics .................................................. 55
Figure 13-2: Proportion of various areas in molecular diagnostic collaborations ................................. 65
-5-